Lumipulse g system

Manufactured by Fujirebio

Sourced in Spain, Belgium, Japan

The Lumipulse G System is an automated immunoassay analyzer designed for in vitro diagnostic testing. It utilizes chemiluminescent enzyme immunoassay (CLEIA) technology to quantitatively measure various analytes in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Lumipulse g kl 6, by Fujirebio (1 mentions) Bdna quantiplex 3, by Bayer (1 mentions) Cobas ampliprep cobas taqman hiv 1 test, by Roche (1 mentions) Cobas ampliprep cobas taqman, by Roche (1 mentions) Cobas amplicor hbv monitor, by Roche (1 mentions) Lumipulse g sars cov 2 ag assay, by Fujirebio (1 mentions)

4 protocols using lumipulse g system

Serum Biomarkers YKL-40 and KL-6 Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

YKL-40 levels were measured in serum samples obtained at each visit by an YKL-40 enzyme immunoassay kit (Quidel, San Diego, CA, USA), in accordance with the manufacturer’s instructions.
KL-6 levels were measured in serum samples obtained at each visit by a chemiluminescent enzyme immunoassay (Lumipulse G KL-6, Fujirebio Iberia SL, Barcelona, Spain) using the Lumipulse G System and in accordance with the manufacturer’s instructions.

Sánchez-Díez S., Gómez-Ollés C., Cruz M.J., de Homdedeu M., Espejo D., Ferrer J., Roca O., Pacheco A, & Muñoz X. (2023). Biomarker Profiles Associated with COVID-19 Severity and Mortality. Current Issues in Molecular Biology, 45(3), 1998-2012.

+ Open protocol

+ Expand

Longitudinal Assessment of HBV and HIV Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum HBV-DNA viral load was quantified at baseline and every 6–12 months by a commercial polymerase chain reaction (PCR)-based assay (COBAS AmpliPrep/COBAS TaqMan, detection limit 12 IU/mL; or COBAS Amplicor HBV Monitor, detection limit 60 IU/mL [Roche Diagnostics Systems, Meylan, France]). Serum HIV-1 RNA viral load was measured at baseline and every 6–12 months using either a branched DNA technique (bDNA Quantiplex 3.0, detection limit 50 copies/mL [Bayer Diagnostics, Cergy-Pontoise, France]) or real-time PCR technique (COBAS AmpliPrep/COBAS TaqMan HIV-1 test, detection limit 40 copies/mL [Roche Molecular Systems, Meylan, France]). Qualitative HBsAg, HBeAg, and antibodies were detected at cohort inclusion and every yearly visit using commercial enzyme immunoassays (EIA).
Serum qHBcrAg (U/mL) was measured at baseline and every 6 months using commercially available, automated HBcrAg chemiluminescence EIA (Lumipulse G System; FujiRebio Europe, Gent, Belgium) [22 (link)]. For levels of qHBcrAg >7 log, a dilution 1/100 was performed as recommended by the manufacturer. In addition, anti-HBc antibodies (both immunoglobulin [Ig]G and IgM) were quantified at baseline and every 6–12 months using ARCHITECT Anti-HBc II assay (Abbott Laboratories, Rungis, France), with an automated ARCHITECT i4000 system.

Cruchet R., Dezanet L.N., Maylin S., Gabassi A., Rougier H., Miailhes P., Lascoux-Combe C., Chas J., Girard P.M., Delaugerre C., Lacombe K, & Boyd A. (2020). Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir. Open Forum Infectious Diseases, 7(7), ofaa215.

+ Open protocol

+ Expand

Detecting SARS-CoV-2 in Breastmilk

Check if the same lab product or an alternative is used in the 5 most similar protocols

Breastmilk samples were centrifuged (twice for 5 minutes each at 2000g), and approximately 200 μL of the resulting supernatant was used for detection and quantitation of SARS-CoV-2 nucleocapsid protein antigens via a chemiluminescent enzyme immunoassay (Lumipulse G SARS-CoV-2 Ag assay with the LUMIPULSE G System; Fujirebio). To avoid false-negative results, an internal control (10 μL) obtained from breastmilk samples of 7 control mothers who were breastfeeding was resuspended with supernatant (1 mL). Antigenic tests were also performed using these samples.

Conti M.G., Terreri S., Piano Mortari E., Albano C., Natale F., Boscarino G., Zacco G., Palomba P., Cascioli S., Corrente F., Capponi C., Mirabella M., Salinas A.F., Marciano A., De Luca F., Pangallo I., Quaranta C., Alteri C., Russo C., Galoppi P., Brunelli R., Perno C.F., Terrin G, & Carsetti R. (2021). Immune Response of Neonates Born to Mothers Infected With SARS-CoV-2. JAMA Network Open, 4(11), e2132563.

+ Open protocol

+ Expand

Lumipulse C-Peptide Immunoassay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lumipulse® C-Peptide immunoassay (Fujirebio, Tokyo, Japan) for the quantitative determination of C-peptide in serum or plasma specimens, is based on CLEIA technology by a twostep sandwich immunoassay method on the fully automated Lumipulse® G System (Fujirebio, Tokyo, Japan). The Lumipulse® C-Peptide uses 30 µL of specimen for each assay. As reported by the manufacturer, the observed range of C-peptide values in apparently healthy subjects was 0.71 -2.58 ng/mL. The precision of Lumipulse® C-Peptide resulted ≤5.1%; Lower Limit of Detection (LLoD) and Quantitation (LLoQ) corresponded to 0.0109 ng/mL. Dilution testing reported that linearity was found in a range of 0.57 -30.00 ng/mL.

Caviglia G.P., Rosso C., Armandi A., Ribaldone D.G., Pellicano R., & Bugianesi E. (2021). Analytical and clinical comparison between two different chemiluminescent enzyme immunoassays for the measurement of C-peptide in serum. Minerva Biotechnology and Biomolecular Research, 33(1).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!